219 related articles for article (PubMed ID: 11355165)
41. Towards Molecular Classification of Meningioma: Evolving Treatment and Diagnostic Paradigms.
Proctor DT; Ramachandran S; Lama S; Sutherland GR
World Neurosurg; 2018 Nov; 119():366-373. PubMed ID: 30138732
[TBL] [Abstract][Full Text] [Related]
42. Endoscopic Endonasal Craniofacial Surgery for Recurrent Skull Base Meningiomas Involving the Pterygopalatine Fossa, the Infratemporal Fossa, the Orbit, and the Paranasal Sinus.
Shin M; Shojima M; Kondo K; Hasegawa H; Hanakita S; Ito A; Kin T; Saito N
World Neurosurg; 2018 Apr; 112():e302-e312. PubMed ID: 29339322
[TBL] [Abstract][Full Text] [Related]
43. Meningioma pathology, genetics, and biology.
Lamszus K
J Neuropathol Exp Neurol; 2004 Apr; 63(4):275-86. PubMed ID: 15099018
[TBL] [Abstract][Full Text] [Related]
44. The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival.
Nakada S; Sasagawa Y; Tachibana O; Iizuka H; Kurose N; Shioya A; Guo X; Yamada S; Nojima T
Brain Tumor Pathol; 2019 Jan; 36(1):7-13. PubMed ID: 30519894
[TBL] [Abstract][Full Text] [Related]
45. A rare case of atypical skull base meningioma with perineural spread.
Walton H; Morley S; Alegre-Abarrategui J
J Radiol Case Rep; 2015 Dec; 9(12):1-14. PubMed ID: 27200171
[TBL] [Abstract][Full Text] [Related]
46. The application of flow cytometry for evaluating biological aggressiveness of intracranial meningiomas.
Lin YW; Tai SH; Huang YH; Chang CC; Juan WS; Chao LC; Wen MJ; Hung YC; Lee EJ
Cytometry B Clin Cytom; 2015; 88(5):312-9. PubMed ID: 25408130
[TBL] [Abstract][Full Text] [Related]
47. Skull base chordoid meningioma: imaging features and pathology.
Soo MY; Ng T; Gomes L; Da Cruz M; Dexter M
Australas Radiol; 2004 Jun; 48(2):233-6. PubMed ID: 15230763
[TBL] [Abstract][Full Text] [Related]
48. High-grade meningiomas: biology and implications.
Bi WL; Prabhu VC; Dunn IF
Neurosurg Focus; 2018 Apr; 44(4):E2. PubMed ID: 29606053
[TBL] [Abstract][Full Text] [Related]
49. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features.
Yang SY; Park CK; Park SH; Kim DG; Chung YS; Jung HW
J Neurol Neurosurg Psychiatry; 2008 May; 79(5):574-80. PubMed ID: 17766430
[TBL] [Abstract][Full Text] [Related]
50. Three risk factors for WHO grade II and III meningiomas: A study of 1737 cases from a single center.
Zhou P; Ma W; Yin S; Li Y; Jiang S
Neurol India; 2013; 61(1):40-4. PubMed ID: 23466838
[TBL] [Abstract][Full Text] [Related]
51. Clinicopathological features of solitary fibrous tumor of the meninges: An immunohistochemical reappraisal of cases previously diagnosed to be fibrous meningioma or hemangiopericytoma.
Suzuki SO; Fukui M; Nishio S; Iwaki T
Pathol Int; 2000 Oct; 50(10):808-17. PubMed ID: 11107053
[TBL] [Abstract][Full Text] [Related]
52. Meningothelioma as the predominant histological subtype of midline skull base and spinal meningioma.
Lee JH; Sade B; Choi E; Golubic M; Prayson R
J Neurosurg; 2006 Jul; 105(1):60-4. PubMed ID: 16871881
[TBL] [Abstract][Full Text] [Related]
53. PS6K amplification characterizes a small subset of anaplastic meningiomas.
Cai DX; James CD; Scheithauer BW; Couch FJ; Perry A
Am J Clin Pathol; 2001 Feb; 115(2):213-8. PubMed ID: 11211609
[TBL] [Abstract][Full Text] [Related]
54. Meningeal tumors histologically mimicking meningioma.
Barresi V; Caffo M; Branca G; Caltabiano R; Tuccari G
Pathol Res Pract; 2012 Oct; 208(10):567-77. PubMed ID: 22885109
[TBL] [Abstract][Full Text] [Related]
55. A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base.
Martinez NL; Khanna O; Farrell CJ
Chin Clin Oncol; 2020 Dec; 9(6):75. PubMed ID: 32819111
[TBL] [Abstract][Full Text] [Related]
56. Immunocytochemical analysis of glucose transporter protein-1 (GLUT-1) in typical, brain invasive, atypical and anaplastic meningioma.
van de Nes JA; Griewank KG; Schmid KW; Grabellus F
Neuropathology; 2015 Feb; 35(1):24-36. PubMed ID: 25168354
[TBL] [Abstract][Full Text] [Related]
57. Adoptive transfer of genetically modified Wilms' tumor 1-specific T cells in a novel malignant skull base meningioma model.
Iwami K; Natsume A; Ohno M; Ikeda H; Mineno J; Nukaya I; Okamoto S; Fujiwara H; Yasukawa M; Shiku H; Wakabayashi T
Neuro Oncol; 2013 Jun; 15(6):747-58. PubMed ID: 23460320
[TBL] [Abstract][Full Text] [Related]
58. The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas.
Sughrue ME; Kane AJ; Shangari G; Rutkowski MJ; McDermott MW; Berger MS; Parsa AT
J Neurosurg; 2010 Nov; 113(5):1029-35. PubMed ID: 20380529
[TBL] [Abstract][Full Text] [Related]
59. Skull base atypical meningioma: long term surgical outcome and prognostic factors.
Wang YC; Chuang CC; Wei KC; Hsu YH; Hsu PW; Lee ST; Wu CT; Tseng CK; Wang CC; Chen YL; Jung SM; Chen PY
Clin Neurol Neurosurg; 2015 Jan; 128():112-6. PubMed ID: 25486076
[TBL] [Abstract][Full Text] [Related]
60. Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas.
Peyre M; Feuvret L; Sanson M; Navarro S; Boch AL; Loiseau H; Kalamarides M
J Neurooncol; 2017 Jul; 133(3):633-639. PubMed ID: 28536991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
